Exact Mass: 334.0205
Exact Mass Matches: 334.0205
Found 47 metabolites which its exact mass value is equals to given mass value 334.0205,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Lormetazepam
Lormetazepam, also known as methyllorazepam or (+-)-lorazepam, is a member of the class of compounds known as 1,4-benzodiazepines. 1,4-benzodiazepines are organic compounds containing a benzene ring fused to a 1,4-azepine. Lormetazepam is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Lormetazepam can be found in potato, which makes lormetazepam a potential biomarker for the consumption of this food product. Lormetazepam is a non-carcinogenic (not listed by IARC) potentially toxic compound. Lormetazepam is a drug which is used for the treatment of short-term insomnia [l927. The Dutch, British, and French system called the System of Objectified Judgement Analysis for assessing whether drugs should be included in drug formularies based on clinical efficacy, adverse effects, pharmacokinetic properties, toxicity, and drug interactions was used to assess lormetazepam. A Dutch analysis using the system found that lormetazepam could be suitable to be included in drug prescribing formularies, although zolpidem, zopiclone, and temazepam had higher scores and thus can be seen as relatively favorable . The primary manifestation of overdosage ranges from drowsiness to coma and symptoms may include ataxia, hypotension, hypotonia, respiratory depression which may lead to death [L927]. Lormetazepam (INN, or methyl-lorazepam, is a drug which is a short to intermediate acting 3-hydroxy benzodiazepine derivative. It possesses hypnotic, anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Lormetazepam is considered a hypnotic benzodiazepine and is officially indicated for moderate to severe insomnia. Lormetazepam is a short-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or falling asleep. Hypnotics should only be used on a short-term basis or, in those with chronic insomnia, on an occasional basis. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CD - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
(5R,6S)-3-(2-Carbamoyloxyethylsulfanyl)-6-(1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Chlorsulfaquinoxaline
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D000890 - Anti-Infective Agents > D013424 - Sulfanilamides
afrostyraxthioside C|methylsulfonylthiomethyl 1-thio-beta-D-glucopyranoside
Lormetazepam
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CD - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
Loramet
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CD - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
3-[4-[(4-CHLOROBENZYL)OXY]PHENYL]-5-(CHLOROMETHYL)-1,2,4-OXADIAZOLE
N-(4-chlorophenyl)-1-(pyrimidin-2-yl)-1H-pyrrole-2-sulfonamide
(Z)-2-(2,4-DICHLORO-5-FLUORO-BENZOYL)-3-ETHOXY-ACRYLIC ACID ETHYL ESTER
Methyl 3-(trifluoromethylsulfonyloxy)-2-naphthoate
N-(3-IODO-4-METHOXY-PYRIDIN-2-YL)-2,2-DIMETHYL-PROPIONAMIDE
ETHANONE, 1-[4-CHLORO-1-(PHENYLSULFONYL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]-
Propanamide, N-(4-iodo-2-methoxy-3-pyridinyl)-2,2-dimethyl-
(2R,3R,4S,5R,6S)-2,3,4,5,6-pentahydroxy-7-oxo-8-phosphonooxyoctanoic acid
2-hydroxy-2-[(2R,3S,4R,5S,6R)-3,4,5,6-tetrahydroxy-6-(phosphonooxymethyl)oxan-2-yl]acetic acid
4-Chloro-6-[5-(4-Methoxyphenyl)-1,2,3-Thiadiazol-4-Yl]benzene-1,3-Diol
5-[(2-chlorophenoxy)methyl]-N-(2-thiazolyl)-2-furancarboxamide
2-[2-(4-Fluoroanilino)-4-thiophen-2-yl-5-thiazolyl]acetic acid
6-bromo-2-[(3-methoxyphenoxy)methyl]-1H-imidazo[4,5-b]pyridin-4-ium
[3-(7-Hydroxy-4-oxochromen-2-yl)phenyl] hydrogen sulate
[3-(3-Hydroxy-4-oxochromen-2-yl)phenyl] hydrogen sulate
H4R antagonist 1
H4R antagonist 1 is a potent and highly selective histamine H4 receptor (H4R) antagonist with an IC50 of 27 nM. H4R antagonist 1 does not show any noticeable binding affinity to other subtypes of histamine receptors, H1R, H2R, and H3R[1].
